Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27426695 | 0.84 | DPP4 (0.42) | DPP4CA12CA1CA2CA9 | |
| SCHEMBL25201049 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL18344965 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL18344966 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL3086236 | 0.76 | USP2 (0.47) | DPP4DPP8DPP9 | |
| SCHEMBL29022290 | 0.76 | USP2 (0.47) | DPP4DPP8DPP9 | |
| SCHEMBL14834279 | 0.74 | — | — | |
| SCHEMBL16054584 | 0.74 | — | — | |
| SCHEMBL925416 | 0.72 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL30300602 | 0.72 | CA12 (0.37) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888241-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029193-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-02-27 | — | — | WO | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-7435734-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-10-14 | — | — | US | disclosed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-7217713-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | DPP4 753/4885CA12 4699/4885CA1 4353/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | DPP4 2801/4885CA12 2052/4885CA1 3342/4885 |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | IMPDH1, REV1, CCNI | DPP4 753/4885CA12 4699/4885CA1 4353/4885 |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, ASS1, REV1 | DPP4 1058/4885CA12 4749/4885CA1 4397/4885 |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | DPP4 890/4885CA12 2961/4885CA1 744/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | DPP4 897/4885CA12 2915/4885CA1 715/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | DPP4 808/4885CA12 4722/4885CA1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.